Leadgene Biosolutions

What Leadgene Biosolutions does

Leadgene Biosolutions Inc. is a Taipei, Taiwan-based biotechnology instruments company founded in 2018 that develops intelligent culture systems for cell line development and real-time metabolic monitoring. The company sells capital equipment to biopharmaceutical firms and academic research institutions, with a stated base of 100+ customers spanning AstraZeneca, Lonza, Amgen, Vertex, Fujifilm, Genmab, Menarini, PTC Therapeutics, Resilience, MeiraGTx, Massachusetts General Hospital, MIT, the Broad Institute, KAUST, NIBRT, Politecnico di Milano, and 23andMe, among others.

The company's technology stack centers on two integrated product lines built around patented programmable pneumatic microplate mixing with integrated real-time dissolved oxygen (DO) and pH sensing. The NEST series (S.NEST 2.0, C.NEST 2.0, and C.BIRD) delivers adjustable mixing at 96-well and 24-well scales with suspension-boost functionality and UV sterilization, targeting upstream bioprocess development, clone selection, and scale-up workflows. The DolphinQ series (DolphinQ and DolphinQ Mini) provides continuous, non-invasive longitudinal monitoring of OCR, ECAR, DO, and pH across the entire culture period without reagents or removal of cells from the incubator. The platform claims 29–42% acceleration of cell line development workflows and high-throughput down-scale modeling of up to 96 parallel conditions at 1–1.6 mL per well. Core IP is protected through granted patents in the US, European Patent Convention, Taiwan, Australia, China, and India, with corresponding global trademarks for the DolphinQ, S.NEST, C.NEST, and C.BIRD brands.

Leadgene operates a direct enterprise field-sales model with quote-based pricing (no public list prices) and FCA delivery terms from its Taiwan facility on 30-day net payment. Revenue is generated primarily through hardware sales of the bioprocessing instruments, supplemented by C.BIRD software licensing, sensor plate calibration files, and maintenance/support services referenced in its general terms and conditions. The company pursues an event-driven and content-driven go-to-market strategy, including participation in BIO 2026 in San Diego as part of a Taipei City Government-organized delegation, alongside a multi-channel digital marketing footprint spanning website content, MailChimp newsletters, YouTube webinars, and social media. It is privately held with 11–50 employees and no disclosed funding rounds, acquisitions, or revenue figures.

Name

Leadgene Biosolutions

Legal name

Leadgene Biosolutions Inc.

Website

https://leadgene-biosolutions.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Leadgene Biosolutions is a Taipei-based biotechnology company that develops intelligent cell culture systems combining programmable pneumatic microplate mixing with real-time dissolved oxygen, pH, and metabolic (OCR/ECAR) monitoring for biopharmaceutical companies and academic research institutions globally.

Ownership category

akta.pro rank

Product category

Bioprocessing Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Cell culture instruments
• Bioprocessing equipment
• Metabolic monitoring systems
• Microplate agitation platforms
• Bioprocess optimization tools

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Bioprocessing Hardware Systems: Sale of proprietary bioprocessing instruments including S.NEST 2.0, C.NEST 2.0, C.BIRD, DolphinQ, and DolphinQ Mini systems. These are capital equipment purchases with associated software (C.BIRD software, sensor plate calibration files). Terms indicate FCA delivery from Taiwan, 30-day net payment, with potential for maintenance and repair services.
2. Software and Calibration Services: C.BIRD software and S.NEST/DolphinQ/DolphinQ Mini sensor plate calibration files are distributed as part of the product ecosystem. Software is subject to end-user license agreement. Maintenance services are referenced in T&Cs as supplemental services.
3. Maintenance and Support Services: Supplemental maintenance and repair services referenced in the company's General Terms and Conditions (Parts B and C), indicating ongoing service contracts for installed base of instruments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Leadgene Biosolutions manufactures and sells intelligent culture systems for cell culture control and monitoring in bioprocess and cellular research applications. The company offers two integrated product lines: the NEST series (S.NEST 2.0, C.NEST 2.0, C.BIRD) for programmable microplate agitation in cell line development, and the DolphinQ series (DolphinQ, DolphinQ Mini) for real-time, long-term metabolic monitoring of dissolved oxygen, pH, OCR, and ECAR.

Product overview

Leadgene Biosolutions offers a unified platform of intelligent culture systems consisting of two integrated product lines: the NEST series (S.NEST 2.0, C.NEST 2.0, C.BIRD) for programmable microplate mixing and cell culture acceleration, and the DolphinQ series (DolphinQ, DolphinQ Mini) for real-time long-term metabolic monitoring. These products work together to provide end-to-end support for cell line development and bioprocess optimization workflows, from single-cell expansion through early-stage clone selection and metabolic characterization.

Differentiator

Problem solved

Functional benefit

Products and services

• S.NEST 2.0

Quantifiable outcome

• Accelerates cell line development workflows by 29–42%
• +2 more outcomes

Named customers20 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Taipei City GovernmentcoreGTM or Marketing Partner · 18 June 2026Leadgene Biosolutions is part of a Taipei City Government-organized delegation of six Taipei-based biotech companies participating in BIO 2026 in San Diego. The delegation represents therapeutics, diagnostics, CDMO services, biosensing, and bioprocess instrumentation sectors, aiming to secure international partnerships and commercialization deals with global pharmaceutical partners. This reflects Taiwan's strategic pivot toward international partnership and commercialization.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oroboros Instruments: Oroboros specializes in high-resolution respirometry (Oroboros O2k) for mitochondrial and cellular metabolism research. Customer testimonials explicitly position DolphinQ as a long-term monitoring alternative to Oroboros systems.
• Hamilton Company: Hamilton offers automated liquid handling, sensors, and cell culture monitoring instrumentation (including DO/pH sensing) for bioprocess and life science labs, overlapping with Leadgene's real-time culture parameter monitoring capability.

Regional players

• Corning Life Sciences: Corning provides cell culture vessels, microplates, and bioprocess products globally; its Corning Microplates are commonly used with Leadgene's S.NEST/C.BIRD systems, making it both a complementary supplier and a competitor for upstream bioprocess budget.

Broad incumbents

• Tecan: Tecan provides laboratory automation, detection, and cell biology instrumentation to biopharma and academic labs, with overlapping capabilities in high-throughput cell-based assay workflows that Leadgene's microplate platform addresses.
• Sartorius: Sartorius is a major bioprocessing equipment vendor (ambr bioreactors, cell culture platforms) serving overlapping biopharma CLD and scale-up customers. Both companies compete for upstream bioprocess workflow spend.
• Cytiva: Cytiva (Danaher) supplies bioprocessing instruments, single-use bioreactors, and cell line development tools to biopharmaceutical manufacturers, overlapping directly with Leadgene's S.NEST/C.NEST and DolphinQ use cases in upstream development.
• Thermo Fisher Scientific: Thermo Fisher provides a broad portfolio of cell culture instruments, analytical tools, and bioprocessing solutions to the same global biopharma and academic customers Leadgene serves, including in metabolic and cell line development workflows.
• Agilent Technologies: Agilent owns the Seahorse XF platform, the dominant instrument for cellular metabolism analysis (OCR/ECAR) that Leadgene's DolphinQ directly competes against. Both target bioprocess and academic researchers measuring mitochondrial function and glycolysis.
• Beckman Coulter Life Sciences: Beckman Coulter (Danaher) supplies cell culture, particle analysis, and bioprocess instruments to the same global research and biopharma customers, with overlapping applications in cell line development and analytical workflows.
• Eppendorf: Eppendorf manufactures shake flasks, bioreactors, and cell culture instrumentation used in clone selection, screening, and bioprocess scale-up — workflows where Leadgene's microplate agitation products compete for budget.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/leadgene-biosolutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leadgene Biosolutions